Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT02216409 |
| Title | Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody |
| Recruitment | Completed |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | Forty Seven, Inc. |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Stanford Cancer Institute | Stanford | California | 94305 | United States | Details | |
| University of Chicago | Chicago | Illinois | 60637 | United States | Details | |
| START Midwest | Grand Rapids | Michigan | 49503 | United States | Details | |
| Memorial Sloan-Kettering Cancer Center | New York | New York | 10065 | United States | Details | |
| University of Oklahoma | Oklahoma City | Oklahoma | 73104 | United States | Details | |
| South Texas Accelerated Research Therapeutics | San Antonio | Texas | 78229 | United States | Details |